Cosmetic material composition for skin Anti-inflammation and skin soothing

Abstract

The present disclosure relates to a cosmetic material composition for skin anti-inflammation and skin soothing. Specifically, the cosmetic material composition according to the present disclosure can achieve an anti-inflammatory effect and a skin soothing effect by controlling the expression of inflammatory skin disease-associated mediators.

Description

Cosmetic composition for skin anti-inflammation and skin soothing

[0001] The present invention relates to a cosmetic composition for skin anti-inflammation and skin soothing, and more specifically, to a cosmetic composition for skin anti-inflammation and soothing that has an anti-inflammatory effect by controlling the expression of mediators related to inflammatory skin diseases.

[0002] 본 발명은 보건복지부의 재원으로 한국보건산업진흥원의 보건의료기술연구개발사업 지원에 의하여 이루어진 것이다(과제고유번호: RS- RS-2023-KH141511).

[0003] Skin inflammation occurs when cells are damaged by various causes, including biological factors such as bacteria and viruses, physical factors such as mechanical irritation, heat, radiation, and electricity, or chemical substances. During this process, substances such as histamine and kinin are released, causing blood vessels to dilate, capillary permeability to increase, and macrophages to accumulate at the site of inflammation. As a result, blood flow increases and edema appears in the inflamed area, while immune cells and antibodies migrate to induce pain and fever. This reaction is one of the defense mechanisms designed to prevent damage to biological tissues.

[0004] Skin inflammatory responses are initiated as a biological reaction to protect the skin from external stimuli or damage, involving various immune cells and inflammation-inducing cytokines. These cytokines include interleukins, chemokines, tumor necrosis factor (TNF), and interferons, while several growth factors play important roles in regulating inflammation and tissue regeneration. Examples include insulin-like growth factor (IGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF).

[0005] Currently, synthetic drugs such as ibuprofen, antihistamines, steroids, and immunosuppressants are used to treat inflammatory skin diseases, but these drugs only provide temporary symptom relief or can cause hypersensitivity reactions and worsening of the immune system. In addition, anti-inflammatory cosmetic compositions using natural extracts have been attempted, but their actual application has been limited due to skin irritation, discoloration, and solubility issues.

[0006] Against this backdrop, research was conducted on specific compounds that inhibit the activity of inflammation-inducing cytokines, and as a result, it was discovered that certain alcohol or amino acid-derived compounds have a low potential for cytotoxicity and allergy induction, and are effective in inhibiting the production of inflammation-inducing cytokines such as IL-8 and IL-17.

[0007] Based on this, the present invention aims to provide an anti-inflammatory cosmetic composition that alleviates inflammation and soothes the skin.

[0008] The present invention aims to provide a cosmetic composition for skin anti-inflammatory and skin soothing that can alleviate inflammation and soothe the skin by regulating the expression of mediators related to inflammatory skin diseases.

[0009] The present disclosure provides a cosmetic composition for skin anti-inflammatory and skin soothing comprising a compound represented by the following chemical formula 1 and a compound represented by chemical formula 2.

[0010] [Chemical Formula 1]

[0011]

[0012] [Chemical Formula 2]

[0013]

[0014] (In the above chemical formulas 1 and 2,

[0015] R1 to R3 are independently straight-chain or branched-chain (C1-C30)alkyl, (C2-C30)alkenyl, (C2-C30)alkynyl, (C1-C30)alkoxy, or hydroxy(C1-C30)alkyl, and

[0016] L1 to L3 are independently single bonds or (C1-C30)alkylenes.

[0017] According to one embodiment, R1 and R3 are independently straight-chain or branched-chain (C1-C20)alkyl, R2 is straight-chain or branched-chain (C1-C10)alkyl, and L1 to L3 are independently single-bond or (C1-C10)alkylene.

[0018] According to one embodiment, R1 and R3 may independently be straight-chain (C5-C10)alkyl, R2 may be straight-chain (C1-C5)alkyl, and L1 to L3 may independently be (C1-C5)alkylene.

[0019] According to one embodiment, R1 and R3 may be nonyl, R2 may be methyl, and L1 to L3 may be methylene.

[0020] The cosmetic composition for skin anti-inflammatory and skin soothing of the present disclosure may comprise 0.5 to 2 moles of a compound represented by Formula 2 for every 1 mole of a compound represented by Formula 1.

[0021] The cosmetic composition for skin anti-inflammatory and skin soothing of the present disclosure may contain the compound represented by Formula 1 and the compound represented by Formula 2 in an amount of 0.001 to 1 weight% with respect to the total composition.

[0022] The above cosmetic composition may be formulated as a softening lotion, astringent lotion, nourishing lotion, eye cream, nourishing cream, massage cream, cleansing cream, cleansing foam, cleansing water, powder, essence, or pack.

[0023] The present disclosure provides a pharmaceutical composition for the prevention or treatment of dermatitis comprising a compound represented by the following chemical formula 1 and a compound represented by chemical formula 2.

[0024] [Chemical Formula 1]

[0025]

[0026] [Chemical Formula 2]

[0027]

[0028] (In the above chemical formulas 1 and 2,

[0029] R1 to R3 are independently (C1-C30)alkyl, (C2-C30)alkenyl, (C2-C30)alkynyl, (C1-C30)alkoxy or hydroxy(C1-C30)alkyl, and

[0030] L1 to L3 are independently single bonds or (C1-C30)alkylenes.

[0031] According to one embodiment, R1 and R3 are independently (C5-C10)alkyl, and

[0032] The above R2 is (C1-C5)alkyl, and the above L1 to L3 may be (C1-C5)alkylenes independently of each other.

[0033] According to one embodiment, R1 and R3 may be nonyl, R2 may be methyl, and L1 to L3 may be methylene.

[0034] The above pharmaceutical composition may inhibit one or more inflammatory factors selected from TNF-α, IL-6, and IL-8.

[0035] The above dermatitis may be atopic dermatitis or psoriasis.

[0036] A cosmetic composition for skin anti-inflammation and skin soothing according to one embodiment of the present invention can effectively prevent inflammatory reactions by inhibiting the regulation of cytokines, thereby exhibiting an excellent anti-inflammatory effect on inflammatory skin diseases, particularly atopic dermatitis or allergic dermatitis.

[0037] 도 1은 본 개시의 실시예 및 비교예의 조성물을 인간의 각질형성세포에 처리하였을 때, qPCR을 통해 분석한 염증 유발 사이토카인(TNF-alpha, IL-6, IL-8)의 mRNA 발현 정도를 나타낸 것이다.

[0038] 도 2는 본 개시의 실시예 및 비교예의 조성물을 인공 피부 모델(EpiDermFT™)을 처리하여 IHC 염색 처리한 결과 및 IL-6의 발현에 따라 염색된 영역의 비율을 그래프로 나타낸 것이다.

[0039] 도 3은 본 개시의 실시예 및 비교예의 조성물을 인공 피부 모델(EpiDermFT™)을 처리하여 IHC 염색 처리한 결과 및 IL-8의 발현에 따라 염색된 영역의 비율을 그래프로 나타낸 것이다.

[0040] The present invention will be described in detail below. Unless otherwise defined, terms used in this specification should be interpreted as generally understood by those skilled in the art. The drawings and embodiments of this specification are intended to enable those skilled in the art to easily understand and practice the present invention; therefore, details that may obscure the essence of the invention may be omitted from the drawings and embodiments, and the present invention is not limited to the drawings and embodiments.

[0041] The singular form used in this specification may be intended to include the plural form unless specifically indicated otherwise in the context.

[0042] Furthermore, the numerical range used in this invention includes lower and upper limits and all values ​​within the range, increments logically derived from the form and width of the defined range, all of the specified values, and all possible combinations of upper and lower limits of the numerical range defined in different forms. Unless otherwise specifically defined in the specification of this invention, values ​​outside the numerical range that may occur due to experimental error or rounding are also included in the defined numerical range.

[0043] In this specification, terms such as "include," "have," and "have" mean that the features or components described in the specification are present, and unless specifically limited, this does not preclude the possibility that one or more other features or components may be added.

[0044] The term "inflammation" as used in the present invention refers to a phenomenon that occurs for a series of defensive purposes to minimize the reaction and restore the damaged area to its original state when cells or tissues are damaged by any cause. It collectively refers to a condition that causes nerve, blood vessel, lymphatic, fluid, and cellular reactions, resulting in pain, swelling, redness, fever, etc., and causing functional impairment. Inflammatory skin diseases resulting from the above inflammation may be one or more selected from the group consisting of atopic dermatitis, psoriasis, contact dermatitis, eczematous dermatitis, photodermatitis, seborrheic dermatitis, herpetic dermatitis, lichen planus, lichen sclerosus, pyoderma gangrene, pemphigus, bullous epidermolysis, systemic sclerosis, dermatomyositis, polymyositis, inflammatory myopathy, leprosy, and Sézary syndrome, and allergic dermatitis such as urticaria, insect allergy, food allergy, and drug allergy also falls into the same category.

[0045] The terms "IL-6" and "IL-8" as used in this invention are examples of inflammation-inducing cytokines whose expression continuously increases due to inflammatory responses; therefore, inhibiting them is crucial for alleviating inflammation.

[0046] The term "improvement" as used in this invention refers to any act in which an inflammatory condition is improved or beneficially altered due to the cosmetic composition according to this invention.

[0047] As a result of further research on the degree of inhibition of the activity of inflammation-inducing cytokines, which are mediators related to inflammatory skin diseases, the applicant confirmed that when a compound represented by the following chemical formula 1 and a compound represented by the following chemical formula 2 are simultaneously included, the anti-inflammatory effect is significantly increased.

[0048] In other words, according to the present invention, a significantly superior anti-inflammatory effect can be achieved by inhibiting the production of mediators related to inflammatory skin diseases.

[0049] The present disclosure provides a cosmetic composition for skin anti-inflammatory and skin soothing comprising a compound represented by the following chemical formula 1 and a compound represented by chemical formula 2.

[0050] [Chemical Formula 1]

[0051]

[0052] [Chemical Formula 2]

[0053]

[0054] (In the above chemical formulas 1 and 2,

[0055] R1 to R3 are independently straight-chain or branched-chain (C1-C30)alkyl, (C2-C30)alkenyl, (C2-C30)alkynyl, (C1-C30)alkoxy, or hydroxy(C1-C30)alkyl, and

[0056] L1 to L3 are independently single bonds or (C1-C30)alkylenes.

[0057] The substituents comprising the “alkyl,” “alkoxy,” and other “alkyl” portions described in the present invention may be in a straight-chain or branched-chain form, and the straight-chain form is preferred. Furthermore, the alkyl, alkoxy, and hydroxyalkyl according to the present invention have 1 to 7 carbon atoms in a straight-chain form or have a straight-chain form with said number of carbon atoms, but it is also known that having 8 to 30 carbon atoms is one embodiment of the present invention.

[0058] In addition, the “alkenyl” described in the present invention is primarily a straight-chain hydrocarbon containing one or more double bonds, and examples include but are not limited to ethenyl, prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl, prop-2-en-2-yl, but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-diene-1-yl, buta-1,3-diene-2-yl, etc.

[0059] The “alkynyl” described in the present invention is primarily a straight-chain hydrocarbon containing one or more triple bonds, and examples include ethinyl, prop-1-in-1-yl, prop-2-in-1-yl, but-1-in-1-yl, but-1-in-3-yl, but-3-in-1-yl, etc., but are not limited thereto.

[0060] In addition, a composition according to one embodiment of the present invention can achieve a skin soothing effect by simultaneously containing a compound represented by Formula 1 and a compound represented by Formula 2 as active ingredients. Specifically, according to the present invention, an effect of soothing skin that has become sensitive due to inflammation can be achieved.

[0061] That is, a cosmetic composition according to one embodiment of the present invention is primarily used for anti-inflammatory purposes, but can also be usefully utilized as a composition for moisturizing the skin, promoting the differentiation of skin keratinocytes, and / or restoring skin barrier function.

[0062] In one embodiment of the present invention, the compound is a very stable substance that is easy to formulate and exhibits an anti-inflammatory effect particularly effective for atopic dermatitis or allergic dermatitis. Specifically, R1 and R3 are independently straight-chain or branched-chain (C1-C20)alkyl, R2 is straight-chain or branched-chain (C1-C10)alkyl, and L1 to L3 are independently single-bond or (C1-C10)alkylene.

[0063] According to one embodiment, R1 and R3 may independently be straight-chain (C5-C10)alkyl, R2 may be straight-chain (C1-C5)alkyl, and L1 to L3 may independently be (C1-C5)alkylene.

[0064] According to one embodiment, R1 and R3 may be nonyl, R2 may be methyl, and L1 to L3 may be methylene.

[0065] The cosmetic composition for skin anti-inflammatory and skin soothing of the present disclosure may contain 0.5 to 2 moles of a compound represented by Formula 2 for every 1 mole of a compound represented by Formula 1, and specifically, for every 1 mole, the lower limit may be 0.5, 0.6, 0.7, 0.8, or 0.9 moles, and the upper limit may be 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, or 1.1 moles.

[0066] The cosmetic composition for skin anti-inflammatory and skin soothing of the present disclosure may contain the compound represented by Formula 1 and the compound represented by Formula 2 in an amount of 0.001 to 1 weight% with respect to the total composition, specifically, the lower limit may be 0.001, 0.003, 0.005, 0.007, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.1 weight%, and the upper limit may be 1, 0.95, 0.9, 0.85, 0.8, 0.75, 0.7, 0.65, 0.6, 0.55, 0.5, 0.45, 0.4, 0.35, or 0.3 weight%.

[0067] The cosmetic composition according to the present disclosure may be prepared by including suitable additives commonly used. In this case, examples of said additives may include one or more aqueous additives selected from purified water, stabilizers, emulsifiers, thickeners, moisturizers, liquid crystal film strengtheners, pH adjusters, antimicrobial agents, water-soluble polymers, coating agents, metal ion chelating agents, amino acids, organic amines, polymer emulsions, pH adjusters, skin nutrients, antioxidants, antioxidant aids, preservatives, fragrances, etc.; and one or more oily additives selected from oils, waxes, hydrocarbon oils, higher fatty acid oils, higher alcohols, synthetic ester oils, and silicone oils, etc.

[0068] The above aqueous additives are not limited to raw materials commonly used in the industry, and specific examples include glycerin, dipropylene glycol, butylene glycol, pentylene glycol, methylpropanediol, sorbitol, diglycerin, erythritol, pentaerythritol, polybutylene glycol-10, polyglycerin-3, polyglycerin-4, polyglycerin-6, polyglycerin-10, polyglycerin-20, polyglycerin-40, sorbes-5, sorbes-6, sorbes-20, sorbes-30, sorbes-40, inositol, maltitol, maltose, mannan, mannitol, mannose, lactitol, lactose, dihydroxypropyl PG-glucoside, dithioctanediol, fructose, glucamine, methylglucarmine, glucose. 1,2,6-Hexanethiol, Methylgluceth-10, Methylgluceth-20, Ozonized Glycerin, Phytantriol, Thioglycerin, Threitol, Trimethylolpropane, Xylitol, EDTA, Guar Gum, Quince Seed, Carrageenan, Galactan, Gum Arabic, Pectin, Mannan, Starch, Xanthan Gum, Cuddlan, Methylcellulose, Hydroxyethylcellulose, Carboxymethyl Cellulose, Methylhydroxypropyl Cellulose, Chondroitin Sulfate, Dermatan Sulfate, Glycogen, Heparan Sulfate, Hyaluronic Acid, Sodium Hyaluronate, Tragant Gum, Keratan Sulfate, Chondroitin, Mucoitin Sulfate, Hydroxyethyl Guar Gum, Carboxymethyl Guar Gum, Dextran, Kerat Sulfate, Locust Bean Gum, It may be one or more selected from succinoglucan, caronic acid, chitin, chitosan, carboxymethylchitin, agar, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium polyacrylate, polyethylene glycol, bentonite, methylparaben, propylparaben, phenoxyethanol, 1,2-hexanediol, ethylhexylglycerin, etc.In addition, the above-mentioned oily additives are not limited to raw materials commonly used in the industry, and examples include liquid oils such as olive oil, camellia oil, jojoba oil, triglycerides, trioctoglycerin, and triisopalmitic acid glycerin; solid oils such as palm oil, hydrogenated palm oil, palm oil, hydrogenated oil, and hydrogenated castor oil; and beeswax, candelilla wax, carnauba wax, lanolin, and jojoba wax. Examples of hydrocarbon oils include liquid paraffin, squalene, petroleum jelly, and microcrystalline wax. Examples of higher fatty acids include waxes such as lauric acid, myristic acid, palmitic acid, stearic acid, and behenic acid; cetyl alcohol, stearyl alcohol, behenyl alcohol, myristyl alcohol, and cetostearyl alcohol; and synthetic ester oils include higher alcohols such as isopropyl myristate, cetyl octanoate, octyldodecyl myristate, isopropyl palmitate, hexyl laurate, myristyl myristate, cetyl lactate, isocetyl isostearate, neopentyl glycol dicaprate, ethylhexylglycerin, cetyl ethylhexanoate, ethylhexyl palmitate, and cetostearyl alcohol; chain-type silicone oils such as dimethylpolysiloxane, methylphenylpolysiloxane, and methylhydrogenpolysiloxane; and cyclic silicone oils such as dodecamethylcyclohexasiloxane, octamethylcyclotetrasiloxane, and decamethylcyclopentasiloxane. It may be selected from the back, but is not limited to this.

[0069] It is obvious that a cosmetic composition according to one embodiment of the present disclosure can be prepared in the form of a general emulsion formulation and a solubilized formulation, etc., by using a commonly known manufacturing method in addition to the manufacturing method specifically disclosed in the present invention.

[0070] According to one embodiment, the cosmetic composition may be formulated as a softening lotion, an astringent lotion, a nourishing lotion, an eye cream, a nourishing cream, a massage cream, a cleansing cream, a cleansing foam, a cleansing water, a powder, an essence, or a pack.

[0071] The present disclosure provides a pharmaceutical composition for the prevention or treatment of dermatitis comprising a compound represented by the following chemical formula 1 and a compound represented by chemical formula 2.

[0072] [Chemical Formula 1]

[0073]

[0074] [Chemical Formula 2]

[0075]

[0076] (In the above chemical formulas 1 and 2,

[0077] R1 to R3 are independently (C1-C30)alkyl, (C2-C30)alkenyl, (C2-C30)alkynyl, (C1-C30)alkoxy or hydroxy(C1-C30)alkyl, and

[0078] L1 to L3 are independently single bonds or (C1-C30)alkylenes.

[0079] A pharmaceutical composition according to one embodiment of the present disclosure may include a pharmaceutically acceptable carrier according to a method that can be easily practiced by a person skilled in the art to which the invention pertains. The pharmaceutically acceptable carrier included in the pharmaceutical composition is one that is commonly used in formulations, such as lactose,

[0080] It may be dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil, but is not limited thereto.

[0081] The pharmaceutical composition for the prevention or treatment of dermatitis of the present disclosure may additionally include, in addition to the above components, a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, or a preservative.

[0082] The pharmaceutical composition for the prevention or treatment of dermatitis disclosed in this invention may be manufactured using commonly known manufacturing methods in addition to the manufacturing method specifically disclosed in this invention, and may be formulated into an appropriate form as intended. Specific examples thereof include, but are not limited to, forms such as lotions, ointments, gels, creams, patches, and sprays.

[0083] The pharmaceutical composition for preventing or treating dermatitis of the present disclosure has an effect of improving inflammatory skin diseases. In particular, the dermatitis may be dermatitis such as abscess, acne, localized curettage dermatitis, allergic contact dermatitis, poison ivy dermatitis, seborrheic dermatitis, generalized exfoliative dermatitis, congestive dermatitis, perioral dermatitis, and psoriasis, and specifically may be atopic dermatitis or psoriasis.

[0084] According to one embodiment, in a pharmaceutical composition for the prevention or treatment of dermatitis of the present disclosure, R1 and R3 may independently be (C5-C10)alkyl, R2 may be (C1-C5)alkyl, and L1 to L3 may independently be (C1-C5)alkylene.

[0085] According to one embodiment, R1 and R3 may be nonyl, R2 may be methyl, and L1 to L3 may be methylene.

[0086] The above pharmaceutical composition may inhibit one or more inflammatory factors selected from TNF-α, IL-6, and IL-8, but is not limited thereto.

[0087] Hereinafter, the cosmetic composition for skin anti-inflammatory and skin soothing according to the present invention will be described in more detail through specific examples. However, the following examples are merely for reference to explain the present invention in detail, and the present invention is not limited thereto and may be implemented in various forms. Furthermore, the terms used in the description of the present invention are intended only to effectively describe specific examples and are not intended to limit the present invention.

[0088] [Example 1]

[0089] 등록특허공보 KR10-2264354B1로부터 제조된 화학식 3의 N-(1-옥소데실)세린 메틸에스터와 등록특허공보 KR10-2137381B1로부터 제조된 하기 화학식 4의 N-(2-히드록시-1-(히드록시메틸)에틸)데칸아마이드를 각각 1.0wt%로 포함하는(into H2O) 조성물을 제조하였다.

[0090] [Chemical Formula 3]

[0091]

[0092] [Chemical Formula 4]

[0093]

[0094] [Comparative Example 1]

[0095] A composition (into H2O) containing 1.0 wt% of N-(2-hydroxy-1-(hydroxymethyl)ethyl)decaneamide represented by the following chemical formula 4 was prepared.

[0096] [Chemical Formula 4]

[0097]

[0098] [Comparative Example 2]

[0099] A composition containing 1.0 wt% of N-(1-oxodecyl)serine methyl ester represented by the following chemical formula 3 (into H2O) was prepared.

[0100] [Chemical Formula 3]

[0101]

[0102] [Evaluation Example 1] Evaluation of Anti-inflammatory Efficacy

[0103] mRNA expression measurement

[0104] To measure the anti-inflammatory efficacy, atopic dermatitis was induced in human keratinocytes using Poly I:C, and the mRNA expression levels of the cells were measured when treated with the above examples and comparative examples. To induce atopic dermatitis, media containing Poly(I:C) were used, and human keratinocytes were treated for 24 hours with the compounds of Formula 3 and Formula 4 at concentrations of 25 μM each in Example 1, the compound of Formula 4 at 50 μM in Comparative Example 1, and the compound of Formula 3 at 50 μM in Comparative Example 2.

[0105] Subsequently, the expression levels of inflammation-inducing cytokines (TNF-alpha, IL-6, IL-8) were evaluated using qPCR, and the results are shown in Figure 1 below.

[0106] IHC staining

[0107] Media containing Poly(I:C) was used to induce atopic dermatitis in 3D culture tissue (EpiDerm Full Thickness 400) sold by MatTek, and the final concentrations of the compounds were such that Formula 3 (0.05%) and Formula 4 (0.05%) in Example 1, Formula 4 was 0.1% in Comparative Example 1, and Formula 3 was 0.1% in Comparative Example 2, and the 3D culture tissue was treated for 48 hours. Subsequently, the 3D culture tissue was stained with IHC to observe IL-6 and IL-8 expression, and the results are shown in Figures 2 and 3.

[0108] According to FIGS. 1 to 3, when compared to Comparative Examples 1 and 2, it can be confirmed that Example 1 significantly reduced the expression of all three types of inflammation-inducing cytokines (TNF-alpha, IL-6, IL-8). Accordingly, it is believed that the anti-inflammatory effect is maximized when the compounds disclosed in Chemical Formula 3 and Chemical Formula 4 are included simultaneously.

[0109] As described above, the present invention has been explained by specific details, limited embodiments, and comparative examples; however, these are provided merely to aid in a more comprehensive understanding of the invention, and the invention is not limited to the above embodiments. Those skilled in the art can make various modifications and variations from this description.

[0110] Accordingly, the scope of the present invention is not limited to the described embodiments, and all things equivalent to or having equivalent variations to the claims set forth below, as well as the claims set forth below, shall be considered to fall within the scope of the concept of the present invention.

Claims

1. A cosmetic composition for skin anti-inflammatory and skin soothing, comprising a compound represented by the following chemical formula 1 and a compound represented by chemical formula 2. [Chemical Formula 1] [Chemical Formula 2] (In the above chemical formulas 1 and 2, R1 to R3 are independently straight-chain or branched-chain (C1-C30)alkyl, (C2-C30)alkenyl, (C2-C30)alkynyl, (C1-C30)alkoxy, or hydroxy(C1-C30)alkyl, and L1 to L3 are independently single bonds or (C1-C30)alkylenes.

2. In Paragraph 1, The above R1 and R3 are independently straight-chain or branched-chain (C1-C20) alkyls, and The above R2 is a straight-chain or branched-chain (C1-C10) alkyl, and The above L1 to L3 are independently single bonds or (C1-C10)alkylenes, a cosmetic composition for skin anti-inflammatory and skin soothing.

3. In Paragraph 1, The above R1 and R3 are independently straight-chain (C5-C10) alkyls, and The above R2 is a straight-chain (C1-C5) alkyl, and The above L1 to L3 are independently (C1-C5)alkylenes, a cosmetic composition for skin anti-inflammatory and skin soothing.

4. In Paragraph 1, The above R1 and R3 are nonyl, and The above R2 is methyl, and The above L1 to L3 are methylene, a cosmetic composition for skin anti-inflammatory and skin soothing.

5. In Paragraph 1, A cosmetic composition for skin anti-inflammatory and skin soothing, wherein the composition comprises 0.5 to 2 moles of a compound represented by Formula 2 for every 1 mole of a compound represented by Formula 1.

6. In Paragraph 1, A cosmetic composition for skin anti-inflammatory and skin soothing, comprising a compound represented by Chemical Formula 1 and a compound represented by Chemical Formula 2 in an amount of 0.001 to 1 weight% based on the total composition.

7. In Paragraph 1, The above cosmetic composition is formulated as a softening lotion, an astringent lotion, a nourishing lotion, an eye cream, a nourishing cream, a massage cream, a cleansing cream, a cleansing foam, a cleansing water, a powder, an essence, or a pack, and is a cosmetic composition for skin anti-inflammatory and skin soothing.

8. A pharmaceutical composition for the prevention or treatment of dermatitis comprising a compound represented by the following chemical formula 1 and a compound represented by chemical formula 2. [Chemical Formula 1] [Chemical Formula 2] (In the above chemical formulas 1 and 2, R1 to R3 are independently (C1-C30)alkyl, (C2-C30)alkenyl, (C2-C30)alkynyl, (C1-C30)alkoxy or hydroxy(C1-C30)alkyl, and L1 to L3 are independently single bonds or (C1-C30)alkylenes.

9. In Paragraph 8, The above R1 and R3 are independently (C5-C10)alkyl, and The above R2 is a (C1-C5)alkyl, and The above L1 to L3 are independently (C1-C5)alkylenes, a pharmaceutical composition for the prevention or treatment of dermatitis.

10. In Paragraph 8, The above R1 and R3 are nonyl, and The above R2 is methyl, and The above L1 to L3 are methylene, a pharmaceutical composition for the prevention or treatment of dermatitis.

11. In Paragraph 8, The above pharmaceutical composition is a pharmaceutical composition for the prevention or treatment of dermatitis that inhibits one or more inflammatory factors selected from TNF-α, IL-6, and IL-8.

12. In Paragraph 8, A pharmaceutical composition for the prevention or treatment of dermatitis, wherein the above-mentioned dermatitis is atopic dermatitis or psoriasis.

Images